Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | 1 | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 1 |
Preleukemia | D011289 | — | — | 1 | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Magrolimab |
INN | magrolimab |
Description | Magrolimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4297985 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 90YIEHRFJ9 (ChemIDplus, GSRS) |